DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Posição atual:
>
>
> This Story

Forward Printable StoryPrint Comment

 

 

Oncology Homepage

Study reports reduction in biopsy procedures performed when Prostate Health Index (phi) testing is used in clinical practice

First patient treated with RayPilot in Turkey

Varian Halcyon treatment system receives Shonin approval

Baptist Hospital's Miami Cancer Institute awarded cancer research and education grant by IBA

ASCO expands TAPUR study enrollment after promising initial treatment outcomes seen

Delta4 Discover transmission detector approved for use by Varian Medical Systems on TrueBeam and Clinac systems

Intraoperative imaging systems market to reach $3.4 billion by 2024

Varian to showcase technologies for enhancing oncology care coordination at AONN+ Conference

United States proton therapy market is expected to reach nearly $1 billion, potentially $7 billion by 2025

Critical prostate cancer research funding saved

New interim results support Imagio Opto-Acoustic (OA) breast imaging system's potential to reduce negative biopsies

Press releases may be edited for formatting or style
SAN ANTONIO, Sept. 24, 2016 /PRNewswire/ -- Seno Medical Instruments, Inc. (Seno Medical), the company pioneering the development of opto-acoustic technology as a tool to improve the process of diagnosing breast cancer, announced today interim results from the company's multicenter, European MAESTRO post-market surveillance and clinical follow-up study. The results demonstrate the potential of its Imagio® opto-acoustic (OA) breast imaging system to provide physicians with vital information needed to determine whether or not a suspicious mass is cancerous, with the goal of reducing the rate of negative biopsies. The data were presented at a clinical symposium at the Annual Scientific Meeting of the European Society of Breast Imaging (EUSOBI), the second largest conference in the world dedicated to breast cancer imaging, on September 24, 2016 in Paris.

"The interim results from MAESTRO add to the growing body of clinical evidence showing that the Imagio opto-acoustic diagnostic tool increases physicians' confidence when differentiating and classifying malignant and benign breast tissue," said the study's principal investigator Ruud Pijnappel, MD, PhD, Radiologist, University Medical Center, Utrecht, NL, who presented the interim analysis. "The improved accuracy that is possible with this technology could help women avoid painful biopsy procedures that sometimes follow false-positive diagnoses."

Story Continues Below Advertisement

OR Tables, Treatment/GYN/Uro Chairs, Transport Stretchers, Hospital/ICU Bed

iMS combines the superior service of Oakworks Medical and advanced manufacturing technology of FAMED Medical Solutions. The goal of iMS, "Connecting Art and Medical Science" goes way beyond product with exceptional CareLink service. Contact us today!



There are over 1.6 million biopsies performed annually1 and recent reported data noted an 81% "false positive" rate of biopsy procedures – the portion of biopsies that do not lead to breast cancer surgery.2 Seno Medical's Imagio breast imaging system, which received its CE Mark in 2014, has the potential to reduce negative biopsies by 43%. Seno Medical is targeting their PMA submission for the Imagio system to the U.S Food and Drug Administration by the end of 2016.

MAESTRO, a controlled, multi-center, observational, post-market surveillance and clinical follow-up study, was designed to assess the diagnostic value (specificity and sensitivity) of Opto-Acoustics to conventional diagnostic ultrasound (CDU) in suspicious masses classified as BI-RADS 4a and 4b. Investigators first performed CDU to reach a diagnosis and decision to biopsy followed by an Imagio OA examination. Two hundred female subjects with undiagnosed suspicious masses enrolled in the study.

The interim analysis of 78 subjects found that following the use of Imagio system, radiologists downgraded BI-RADS categories of the internal ultrasound control-classified BI-RADS 4a masses to BI-RADS 3 or 2 in 75% of cases, and BI-RADS 4b masses to either BI-RADS 3 or 2 in 37.5% of cases. The interim results also showed that Imagio OA also increased specificity to over 43%, with no significant loss in sensitivity. Importantly, clinicians were able to reduce the rate of false-positive diagnoses by 20% for the last 48 subjects evaluated in the study.
  Pages: 1 - 2 - 3 >>

Oncology Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS